Ascendis Pharma (ASND) reported data from the pivotal double-blind placebo-controlled ApproaCH Trial of TransCon CNP, a potential treatment for children with achondroplasia, which Wall Street analysts say could rival BioMarin Pharmaceuticals’ (BMRN) approved drug, Voxzogo. JPMorgan called the… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3984665/-BioMarin-in-spotlight-as-data-suggests-Ascendis-candidate-could-rival-Voxzogo)
previous post
next post